Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ulcerative Colitis (UC) Clear all
Terminated No phase listed Observational

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

NCT00355901
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Visilizumab (Nuvion®; HuM291)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
15
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jul 21, 2026, 6:56 PM EDT
Withdrawn Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

NCT05316220
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02165215
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
33
States / cities
Orange, California • San Diego, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jul 21, 2026, 6:56 PM EDT
Not yet recruiting No phase listed Observational

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT07250815
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
23,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TUDCA as a Therapy for Ulcerative Colitis (UC)

NCT04114292
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tauroursoursodeoxycholic acid, brand name Tudcabil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
Creve Coeur, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

NCT04700449
View directory record Official record
Conditions
Moderate to Severe Ulcerative Colitis
Interventions
Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307, Double-Blind 0.1mg CBP-307
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Mission Hills, California • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jul 21, 2026, 6:56 PM EDT
Not listed Not applicable Interventional

Decentralized Dietary UC Pilot Trial

NCT02357537
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Combined Anti-inflammatory Diet (CAID)
Behavioral
Lead sponsor
Transparency Life Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 21, 2026, 6:56 PM EDT
Completed No phase listed Observational Results available

Anal Human Papillomavirus in Inflammatory Bowel Disease Study

NCT01364896
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
Interventions
Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Not applicable Interventional

Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

NCT00586807
View directory record Official record
Conditions
Ulcerative Colitis, Protein Metabolism, Energy Expenditure
Interventions
Stable amino acid isotopes
Other
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044
View directory record Official record
Conditions
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
LY4268989, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
52
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 4 Interventional Results available

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

NCT00446849
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04677179
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Jul 21, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
emvistegrast, Placebo-to-match emvistegrast
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
57
States / cities
Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting No phase listed Observational

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional

The Influence of a Fasting Mimicking Diet on Ulcerative Colitis

NCT03615690
View directory record Official record
Conditions
Inflammatory Bowel Disease, Diet Modification, Ulcerative Colitis
Interventions
Fasting Mimicking Diet, Regular Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

NCT04543994
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Withdrawn Phase 2 Interventional

Lactobacillus GG in Pediatric Ulcerative Colitis (UC)

NCT00895336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lactobacillus GG
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

NCT04504383
View directory record Official record
Conditions
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
PN-943, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Tucson, Arizona • Garden Grove, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jul 21, 2026, 6:56 PM EDT
Completed No phase listed Observational

Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)

NCT01678300
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Jul 21, 2026, 6:56 PM EDT
Not yet recruiting Not applicable Interventional

VR Therapies for IBD

NCT07590518
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD), Anxiety
Interventions
Distraction VR, VR/AI CBT
Device
Lead sponsor
Brennan Spiegel
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 21, 2026, 6:56 PM EDT